Stroke Prevention in Atrial Fibrillation – Outcomes and Future Directions

依杜沙班 医学 拜瑞妥 阿哌沙班 达比加群 心房颤动 冲程(发动机) 直接凝血酶抑制剂 华法林 蒂米 内科学 重症监护医学 心脏病学 心肌梗塞 溶栓 工程类 机械工程
作者
Katrina A. Mountfort,A. John Camm,Gregory Y.H. Lip,Andreas Goette,Jean‐Yves Le Heuzey
出处
期刊:Arrhythmia & electrophysiology review [Radcliffe Publishing]
卷期号:3 (3): 194-194 被引量:3
标识
DOI:10.15420/aer.2014.3.3.194
摘要

Stroke prevention is central to the management of patients with atrial fibrillation (AF). Vitamin K antagonists (VKAs) are the established and long-standing option for stroke prevention therapy in patients with AF. However, non-VKA oral anticoagulants (NOACs) have recently been developed and demonstrated non-inferior efficacy vs VKA treatment, with fewer limitations in clinical practice and with reduced risks of major bleeding. In order to discuss the usage, efficacy and safety of NOACs, a satellite symposium was held at the Cardiostim/ EHRA Europace Congress in Nice in June 2014. At present, three NOACs, a direct thrombin inhibitor (dabigatran) and two direct factor Xa inhibitors (rivaroxaban and apixaban) have been approved in Europe for stroke prevention in patients with AF. In addition, the once-daily factor Xa inhibitor edoxaban has recently been evaluated in this setting in the phase III Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis In Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48) that compared edoxaban 30 mg once daily (low-dose regimen) with dose-adjusted warfarin (international normalised ratio 2.0-3.0). ENGAGE AF-TIMI 48 was the largest trial with a NOAC to date, and demonstrated that both dosing regimens of once-daily edoxaban were non-inferior to well-managed warfarin treatment for the prevention of stroke or systemic embolism and also provided significant reductions in the risk of haemorrhagic stroke, cardiovascular mortality, major bleeding and intracranial bleeding. In summary, the recent availability of NOACs has enabled physicians to avoid the limitations of VKA therapy in clinical practice and tailor anticoagulant treatment to the individual patient. However, worldwide usage of oral anticoagulant therapy remains suboptimal compared with guideline recommendations, and further dissemination of its benefits may prove helpful.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
贝壳完成签到,获得积分10
刚刚
玛卡巴卡完成签到,获得积分20
1秒前
ubless607的应助被z23采纳,获得10
2秒前
kagurayame发布了新的文献求助30
2秒前
3秒前
嘎嘣脆完成签到 ,获得积分10
3秒前
怡然的冰旋完成签到,获得积分10
3秒前
开放纹发布了新的文献求助10
3秒前
WangJingnan完成签到,获得积分10
3秒前
3秒前
果冻完成签到,获得积分10
3秒前
3秒前
爱德华发布了新的文献求助10
4秒前
方方发布了新的文献求助20
4秒前
llm完成签到,获得积分10
4秒前
隐形曼青的应助被di采纳,获得10
5秒前
5秒前
ping完成签到,获得积分10
5秒前
5秒前
5秒前
小朱朱完成签到 ,获得积分20
6秒前
6秒前
sound完成签到 ,获得积分10
6秒前
烟花的应助被Amos采纳,获得10
6秒前
6秒前
寥若晨星完成签到,获得积分10
6秒前
6秒前
汉堡包的应助被小陈采纳,获得10
7秒前
ping发布了新的文献求助10
7秒前
科研通AI2S的应助被ryy采纳,获得10
7秒前
orixero的应助被苗子采纳,获得10
8秒前
Stone完成签到,获得积分10
8秒前
紫薇的星辰完成签到,获得积分10
8秒前
英姑的应助被凤族无双采纳,获得10
9秒前
英姑的应助被荼蘼采纳,获得10
9秒前
大个的应助被荼蘼采纳,获得10
9秒前
NexusExplorer的应助被荼蘼采纳,获得10
9秒前
dinghongzhen发布了新的文献求助200
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180927
求助须知:如何正确求助?哪些是违规求助? 9570973
关于积分的说明 21815578
捐赠科研通 7777227
什么是DOI,文献DOI怎么找? 3433367
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479346